Geron Corporation (Nasdaq: GERN), a biopharma company focused on telomerase inhibition therapies, has announced a $375 million financing agreement aimed at supporting the commercial rollout of Rytelo (imetelstat).
The money, which will also be used to advance the firm’s pipeline, comprises $250 million in debt from funds managed by Pharmakon Advisors and a $125 million synthetic royalty agreement with Royalty Pharma (Nasdaq: RPRX).
The funds will support Geron’s planned launch of Rytelo, a first-of-its-kind telomerase inhibitor for lower-risk myelodysplastic syndromes (MDS), in the USA and potentially in the EU.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze